| Identification | Back Directory | [Name]
J30-8 | [CAS]
2366255-71-0 | [Synonyms]
J30-8
J-30-8,J308,J30 8
2H-Indol-2-one, 3-[2-[(2-chlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene]-5-fluoro-1,3-dihydro-, (3Z)- | [Molecular Formula]
C17H9ClFN3O2S | [MDL Number]
MFCD05026464 | [MOL File]
2366255-71-0.mol | [Molecular Weight]
373.79 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [color ]
Brown to red | [InChI]
1S/C17H9ClFN3O2S/c18-10-3-1-2-4-12(10)21-17-22-16(24)14(25-17)13-9-7-8(19)5-6-11(9)20-15(13)23/h1-7H,(H,20,23)(H,21,22,24)/b14-13- | [InChIKey]
HNOFQKYBQYGFNQ-YPKPFQOOSA-N | [SMILES]
Fc1cc2c(cc1)NC(=O)\C\2=C3/SC(=NC/3=O)Nc4c(cccc4)Cl |
| Hazard Information | Back Directory | [Description]
J30-8 is a potent and isoform-selective inhibitor of c-Jun N-terminal kinase 3 (JNK3) with an IC50 of 40 nM, which 2500-fold isoform selectivity against JNK1α1 and JNK2α2. J30-8 exhibits neuroprotective activity in vitro and potential for the treatment of neurodegenerative diseases[1].
JNK3|40 nM (IC50)
| [Uses]
J30-8 is a potent and isoform-selective inhibitor of c-Jun N-terminal kinase 3 (JNK3) with an IC50 of 40 nM, which 2500-fold isoform selectivity against JNK1α1 and JNK2α2. J30-8 exhibits neuroprotective activity in vitro and potential for the treatment of neurodegenerative diseases[1]. | [IC 50]
JNK3: 40 nM (IC50) | [References]
[1]. Dou X, et al. Multistage Screening Reveals 3-Substituted Indolin-2-one Derivatives as Novel and Isoform-Selective c-Jun N-terminal Kinase 3 (JNK3) Inhibitors: Implications to Drug Discovery for Potential Treatment of Neurodegenerative Diseases. J Med Chem. 2019 Jul 25;62(14):6645-6664. |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|